Immutep (IMMP) has released an update.
Immutep Limited, a biotech firm pioneering LAG-3 immunotherapies, has completed patient enrollment for the Phase II AIPAC-003 trial targeting metastatic breast cancer. The study, which enrolled 65 patients who have exhausted endocrine therapy, aims to identify the optimal dose of eftilagimod alpha in combination with paclitaxel. The company promises updates following comprehensive data analysis and encourages the public to find more details on clinicaltrials.gov.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
